Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial

BACKGROUND AND AIMS: To report results from VISIBLE 2, a randomised, double-blind, placebo-controlled, phase 3 trial evaluating a new subcutaneous [SC] vedolizumab formulation as maintenance treatment in adults with moderately to severely active Crohn’s disease [CD]. METHODS: Following open-label ve...

Descripción completa

Detalles Bibliográficos
Autores principales: Vermeire, Séverine, D’Haens, Geert, Baert, Filip, Danese, Silvio, Kobayashi, Taku, Loftus, Edward V, Bhatia, Siddharth, Agboton, Christian, Rosario, Maria, Chen, Chunlin, Zhang, Wenwen, Kisfalvi, Krisztina, Sandborn, William J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797168/
https://www.ncbi.nlm.nih.gov/pubmed/34402887
http://dx.doi.org/10.1093/ecco-jcc/jjab133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797168/
https://www.ncbi.nlm.nih.gov/pubmed/34402887
http://dx.doi.org/10.1093/ecco-jcc/jjab133

Ejemplares similares